407 related articles for article (PubMed ID: 35051989)
1. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
Cheng SMS; Mok CKP; Leung YWY; Ng SS; Chan KCK; Ko FW; Chen C; Yiu K; Lam BHS; Lau EHY; Chan KKP; Luk LLH; Li JKC; Tsang LCH; Poon LLM; Hui DSC; Peiris M
Nat Med; 2022 Mar; 28(3):486-489. PubMed ID: 35051989
[TBL] [Abstract][Full Text] [Related]
2. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
[TBL] [Abstract][Full Text] [Related]
3. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
Cheng SS; Mok CK; Li JK; Ng SS; Lam BH; Jeevan T; Kandeil A; Pekosz A; Chan KC; Tsang LC; Ko FW; Chen C; Yiu K; Luk LL; Chan KK; Webby RJ; Poon LL; Hui DS; Peiris M
J Clin Virol; 2022 Nov; 156():105273. PubMed ID: 36081282
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
[TBL] [Abstract][Full Text] [Related]
7. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
8. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines.
Peiris M; Cheng S; Mok CKP; Leung Y; Ng S; Chan K; Ko F; Yiu K; Lam B; Lau E; Chan K; Luk L; Li J; Tsang L; Poon L; Chen C; Hui D
Res Sq; 2022 Jan; ():. PubMed ID: 35018372
[TBL] [Abstract][Full Text] [Related]
10. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
11. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
12. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N; Kanokudom S; Auphimai C; Assawakosri S; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Puenpa J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
J Med Virol; 2022 Dec; 94(12):5713-5722. PubMed ID: 35924475
[TBL] [Abstract][Full Text] [Related]
13. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
[TBL] [Abstract][Full Text] [Related]
16. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
[TBL] [Abstract][Full Text] [Related]
18. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
